Chronic lymphocytic leukemia.

[Chronic lymphocytic leukemia]. Presse Med. 2019 Aug 22;: Authors: Jacque N, Leblond V Abstract Chronic lymphocytic leukemia is the most frequent adult leukemia. Eighty per cent of the patients are asymptomatic at diagnosis and 30% of the patients will be never treated. The diagnosis is based on the blood smear examination and immunophenotyping by flow cytometry of blood lymphocytes. The first line option is immunochemotherapy in 90% of the patients without genetic abnormalities associated with chemo resistance. The use of new compounds targeting different pathways is more frequent especially in relapsing patients and could be an alternative to the chemotherapy in the future. Asymptomatic patients with a stable disease assessed by the specialist can be followed by the general practitioner with a blood count and clinical examination every six months or once a year. PMID: 31447332 [PubMed - as supplied by publisher]
Source: Presse Medicale - Category: General Medicine Authors: Tags: Presse Med Source Type: research

Related Links:

Publication date: Available online 12 November 2019Source: Pharmacological ResearchAuthor(s): Zhuojun Liu, Jia Liu, Tianming Zhang, Mingxia Shi, Xiaofang Chen, Yun Chen, Jian YuAbstractReceptor tyrosine kinase-like orphan receptor 1 (ROR1) is an onco-embryonic antigen presented on chronic lymphocytic leukemia (CLL), but not on normal adult tissues, which promotes CLL-cell survival. Here, ROR1 was identified as a new client of Heat Shock Protein 90 (HSP90) via a mass spectrometry-based screen for ROR1-associated partners followed by co-immunoprecipitation (co-IP) analysis. A binding motif (ELHHPNIV) on ROR1 for HSP90 was re...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Contributors : Y Perkarsky ; C M CroceSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensWe analyzed small RNA sequencing data from CD5+/CD19+ B cells of a cohort of indolent and aggressive CLL patients compared with CD19+ B-cells of healthy donors.We identified tsRNA signatures in indolent and aggressive CLL vs. normal B-cells; we also found a drastic dysregulation of the expression of mature tRFs in CLL.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research
ConclusionsThe comprehensive analysis of clinical characteristics, immunophenotypic profiles and cytogenetic features can be helpful in differential diagnosis, especially for patients without an available non-bone marrow biopsy specimen. Universal prognostic factors may help with the early detection of high-risk patients and with stratification in risk-adapted therapy.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger RARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales &Marketing Network) -- The Janssen Pharma... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson &Johnson, IMBRUVICA, ibrutinib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
AbstractHighly effective treatments for chronic lymphocytic leukemia (CLL) have the potential to reduce significant tumor burden to single cells and therefore require sensitive tools to assess for minimal residual disease (MRD) in bone marrow (BM) biopsies. Flow cytometry (FC) is the current gold standard for detection of MRD, but requires a specialized facility, specific antibody panels, collecting hundreds of thousands-to-millions of cells, and personnel with expertise in the analysis and interpretation of FC MRD data, which may not be feasible in many small laboratories. Dual-antibody immunohistochemistry (DA-IHC) can i...
Source: Journal of Hematopathology - Category: Pathology Source Type: research
Conditions:   Lymphoid Leukemia;   Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Interventions:   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Biological: Rituximab;   Drug: Bendamustine;   Drug: Bendamustine Hydrochloride Sponsors:   University of Washington;   National Cancer Institute (NCI);   Bayer Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: Available online 6 November 2019Source: Journal of Geriatric OncologyAuthor(s): Annie M. Jacobsen, David T. Gilbertson, Gobind Tarchand, Vicki A. Morrison
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
We report a patient who developed PJP two months after receiving the first course of Lemtrada, and fully recovered after receiving cotrimoxazole treatment. We should remain vigilant of opportunistic infections in patients who develop pneumonitis and evaluate the need for PJP prophylaxis during Lemtrada treatment.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research
Bone Marrow Transplantation, Published online: 07 November 2019; doi:10.1038/s41409-019-0742-7Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia
Source: Bone Marrow Transplantation - Category: Hematology Authors: Source Type: research
CONCLUSIONS: The clinical roles of PD-1/PD-L1 expression vary between subtypes of lymphoma. Future studies should delineate the prognostic and predictive roles of PD-1 and PD-L1 expression. PMID: 31704289 [PubMed - as supplied by publisher]
Source: International Immunopharmacology - Category: Allergy & Immunology Authors: Tags: Int Immunopharmacol Source Type: research
More News: Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | General Medicine | Genetics | Leukemia | Papanicolaou (Pap) Smear | Primary Care